Market Intelligence, Clinical Progress, and High-Purity Reagents for Wound Healing, Cardiovascular, and Metabolic Disease Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FGF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FGF1 Recombinant Protein (Wild-Type & Engineered Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native conformation. |
View FGF1 Products |
| Gene Delivery | FGF1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View FGF1 Products |
| Benchmark Ab | Anti-FGF1 Recombinant Antibody High-affinity positive control for neutralization and binding assays. |
View FGF1 Products |
| Validator | FGF1 siRNA Set For knockdown verification in functional cell-based assays. |
View FGF1 Products |
| Related Target A | FGFR1 Primary receptor mediator for FGF1 mitogenic and metabolic signaling pathways. |
View FGFR1 Products |
| Related Target B | FGFR2 Crucial receptor isoform involved in FGF1-mediated tissue repair and epithelial cell proliferation. |
View FGFR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitogenic vs. Non-mitogenic activity differentiation | Engineered mutant FGF1 proteins available alongside WT to validate metabolic vs. proliferative pathways. |
| Thermal instability of wild-type FGF1 | Sequence-verified, highly stable recombinant formulations minimizing protease degradation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live FGF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FGF1 therapeutics is intensifying, with major players shifting focus from traditional wound-healing formulations to engineered non-mitogenic variants for metabolic disorders. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective FGFR activation to bypass systemic mitogenic risks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Engineered Proteins (Agonists) | Salk Institute, Biotech Spin-offs | NASH/MASH, Type 2 Diabetes | Receptor activation profiling (Need high-purity WT and mutant FGF1) |
| Gene Therapy (Plasmid/AdV) | AnGes, Local Biotechs | Critical Limb Ischemia, CAD | Expression validation (Need validated qPCR primers and siRNA) |
| Recombinant Topical Formulations | Various Generic/Biosimilar Developers | Diabetic Foot Ulcers, Wound Healing | Potency & stability assays (Need highly stable recombinant FGF1) |